Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Keryx Biopharmaceuticals
Keryx Biopharmaceuticals
(KERX)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Auryxia
Ferric pyrophosphate citrate
2014-09-05
—
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Perifosine
recurrence
,
brain neoplasms
,
glioblastoma
,
glioma
,
astrocytoma
,
oligodendroglioma
,
neoplasms
,
kidney neoplasms
,
renal cell carcinoma
,
colonic neoplasms
,
gastrointestinal stromal tumors
,
non-small-cell lung carcinoma
,
sarcoma
,
carcinoma
,
chondrosarcoma
,
alveolar soft part sarcoma
,
lung neoplasms
,
waldenstrom macroglobulinemia
,
leukemia
,
lymphoma
,
multiple myeloma
,
plasma cell neoplasms
,
colorectal neoplasms
,
breast neoplasms
Sulodexide
neoplasms
,
non-small-cell lung carcinoma
,
neoplasm metastasis
,
membranoproliferative glomerulonephritis
,
colorectal neoplasms
,
mucinous adenocarcinoma
,
colonic neoplasms
,
adenocarcinoma
,
rectal neoplasms
,
cystadenocarcinoma
,
tinnitus
,
retinal diseases
,
diabetic retinopathy
,
venous insufficiency
,
peripheral arterial disease
,
chronic renal insufficiency
,
venous thromboembolism
,
thromboembolism
,
post-acute covid-19 syndrome
,
recurrence
,
psoriasis
,
randomized controlled trials as topic
,
diabetic nephropathies
,
kidney diseases
,
covid-19
,
albuminuria
,
thrombosis
,
syndrome
,
postphlebitic syndrome
,
postthrombotic syndrome
,
inflammation
,
ischemic stroke
,
vascular diseases
,
peripheral vascular diseases
,
varicose veins
,
stroke
,
ischemia
,
cerebral infarction
,
cardiovascular diseases
,
hypoparathyroidism
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use